Study limitation: Pegcetacoplan could not be directly sourced for comparison; APL-1 (a compstatin derivative) and a pegcetacoplan-similar molecule were used as surrogates — limiting direct head-to-head conclusions | ReachRx
Pharmacological Characterization of a Novel Complement C3 Inhibitor Antibody Fragment
Study limitation reported by the research below: “Pegcetacoplan could not be directly sourced for comparison; APL-1 (a compstatin derivative) and a pegcetacoplan-similar molecule were used as surrogates — limiting direct head-to-head conclusions.”
